The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | J | Antiinfectives for systemic use | |
2 | J01 | Antibacterials for systemic use | |
3 | J01D | Other beta-lactam antibacterials | |
4 | J01DD | Third-generation cephalosporins |
Code | Title | |
---|---|---|
J01DD01 | Cefotaxime | |
J01DD02 | Ceftazidime | |
J01DD03 | Cefsulodin | |
J01DD04 | Ceftriaxone | |
J01DD05 | Cefmenoxime | |
J01DD06 | Latamoxef | |
J01DD07 | Ceftizoxime | |
J01DD08 | Cefixime | |
J01DD09 | Cefodizime | |
J01DD10 | Cefetamet | |
J01DD11 | Cefpiramide | |
J01DD12 | Cefoperazone | |
J01DD13 | Cefpodoxime | |
J01DD14 | Ceftibuten | |
J01DD15 | Cefdinir | |
J01DD16 | Cefditoren | |
J01DD17 | ||
J01DD18 | ||
J01DD51 | ||
J01DD52 | ||
J01DD54 | Ceftriaxone, combinations | |
J01DD58 | ||
J01DD62 | Cefoperazone, combinations | |
J01DD63 | ||
J01DD64 |
Active Ingredient | Description | |
---|---|---|
Cefcapene |
|
|
Cefditoren |
Cefditoren is a cephalosporin with antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). |
|
Cefetamet |
|
|
Cefixime |
Cefixime is an oral third generation cephalosporin which has marked in vitro bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms. |
|
Cefmenoxime |
|
|
Cefoperazone |
Cefoperazone, a third-generation cephalosporin, interferes with cell wall synthesis by binding to the penicillin-binding proteins (PBPs), thus preventing cross-linking of nascent peptidoglycan. Cefoperazone is stable to penicillinases and has a high degree of stability to many beta-lactamases produced by gram-negative bacteria. |
|
Cefotaxime |
Cefotaxime exerts its action by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thereby inhibiting cell wall synthesis. |
|
Cefpodoxime |
Like other beta-lactam drugs, cefpodoxime exerts antibacterial activity by binding to and inhibiting the action of certain bacterial cell wall synthetic enzymes, namely the penicillin binding proteins. |
|
Ceftazidime |
Ceftazidime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. |
|
Cefteram |
|
|
Ceftibuten |
Ceftibuten is a semisynthetic, beta-lactamase-stable, third-generation cephalosporin with antibacterial activity. Ceftibuten binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This results in the weakening of the bacterial cell wall and causes cell lysis. |
|
Ceftriaxone |
Ceftriaxone is an antibacterial for systemic use, a third-generation cephalosporin. It inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs) leading to bacterial cell lysis and death. |
Title | Information Source | Document Type | |
---|---|---|---|
CEDAX Capsule / Oral suspension | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
CEPODEM Film-coated tablet / Suspension | Health Products Regulatory Authority (ZA) | MPI, Generic | |
FORTAZ Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
FORTUM Powder for solution for injection or infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
MEDAXONUM Powder for solution for injection/infusion | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
MEDOCEF Powder for solution for injection / infusion | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
ORELOX Film-coated tablet / Granules | Health Products Regulatory Authority (ZA) | MPI, Generic | |
Rocephin 250mg, 1g and 2g vials | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SPECTRACEF Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
STOPAREN Powder and solvent for solution for injection | MPI, EU: SmPC | ||
SUPRAX Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TRICEF Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
VALORAN Powder for solution for injection or infusion | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |